H.R. 965, the "CREATES Act"; H.R. 2375, the "Preserve Access to Affordable Generics and Biosimilars Act"; H.R. 2374, the "Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act"; and H.R. 2376, the "Prescription P....
Date:
Location:
2141 Rayburn House Office Building, Washington, DC 20515
Text of Legislation
- H.R. 965, the "CREATES Act" (Agreed to by a Voice Vote)
- H.R. 2375, the "Preserve Access to Affordable Generics and Biosimilars Act" (Agreed to by a Voice Vote)
- H.R. 2374, the "Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act" (Agreed to by a Voice Vote)
- H.R. 2376, the "Prescription Pricing for People Act of 2019" (Agreed to by a Voice Vote)
Documents
Subcommittees
Issues:
Antitrust